Stock Report

Download full stock data and analysis for free Last Updated: 18-Oct-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Gujarat Themis Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: GUJTHEM | BSE: 506879

₹373.40

up-down-arrow ₹3.35 (0.91%)

As on 16-Oct-2026IST

Market cap

info icon

₹4,843 Cr

Revenue (TTM)

info icon

₹174 Cr

P/E Ratio

info icon

99.5

P/B Ratio

info icon

4.6

Div. Yield

info icon

0.2 %

Edit peer-selector-edit
Gujarat Themis Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 4,843 34,586 25,275 16,073 14,003
Revenue (₹ Cr)
 174 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 48.69 1,018.97 497.77 603.02 270.18
Net Margin (%)
 27.66 10.47 20.72 22.63 23.29
RoE (%)
 17.63 21.30 28.49 19.61 14.45
Price to Earnings
 99.47 34.20 50.78 26.65 50.85
Price-To-Book
 4.62 6.61 12.50 4.61 6.75

Income Statement (₹ Cr)

Gujarat Themis Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
173.74 9,683.45 2,371.81 2,590.40 1,108.39
Total Income arrow
176.03 9,730.84 2,402.61 2,664.23 1,159.90
Total Expenditure arrow
91.34 7,739.53 1,608.91 1,753.71 720.01
EBITDA arrow
82.40 1,943.92 762.90 836.69 388.38
Depreciation arrow
14.86 425.10 98.11 78.88 74.78
EBIT arrow
67.55 1,518.82 664.79 757.81 313.60
Interest arrow
4.69 148.45 26.33 5.43 0.26
Other Income arrow
2.29 47.39 30.80 73.83 51.50
Exceptional Items arrow
0.00 -27.85 0.00 -25.66 -3.28
Profit before Tax arrow
65.14 1,389.91 669.26 800.55 361.56
Provision for Tax arrow
16.45 370.94 171.48 197.53 91.39
Profit after Tax arrow
48.69 1,018.97 497.77 603.02 270.18

Liabilities (₹ Cr)

Gujarat Themis Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
287.77 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
0.00 -7.58 0.00 0.00 2.51
Non-Current Liabilities arrow
136.51 723.57 345.47 142.73 50.51
Current Liabilities arrow
79.15 3,912.24 710.20 508.04 169.08
Total Liabilities arrow
514.07 9,514.48 2,930.14 4,157.10 2,231.79

Assets (₹ Cr)

Gujarat Themis Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
408.90 3,392.16 1,290.62 1,321.38 957.22
Current Assets arrow
88.78 5,612.10 1,483.13 2,649.36 1,250.11
Total Assets arrow
514.07 9,514.48 2,930.14 4,157.10 2,231.79
Total Debt* arrow
159.87 1,204.08 196.61 0.00 0.00
Net Current Assets arrow
9.64 1,699.86 772.93 2,141.33 1,081.04
Contingent Liabilities arrow
3.36 258.92 13.18 4.82 3.76

Cashflow (₹ Cr)

Gujarat Themis Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
48.78 943.55 346.68 565.41 266.88
Cash Flow from Investing Activities arrow
-172.28 -1,193.06 -423.73 -570.15 -142.72
Cash from Financing Activities arrow
114.93 343.43 20.98 -64.34 -112.88
Net Cash Inflow / Outflow arrow
-8.57 93.92 -56.08 -69.08 11.28

Ratios

Profitability Ratios

 Gujarat Themis Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
18.16 25.25 27.50 24.61 18.04
ROE (%) arrow
17.63 21.30 28.49 19.61 14.45
ROA (%) arrow
12.10 11.42 19.48 16.31 12.66
EBIT Margin (%) arrow
38.88 15.68 28.03 29.25 28.29
Net Margin (%) arrow
27.66 10.47 20.72 22.63 23.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Gujarat Themis Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
17.51 18.36 78.33 7.93 -6.72
EBIT Growth (%) arrow
16.55 30.43 303.07 19.88 -26.64
Net Profit Growth (%) arrow
9.17 32.39 182.61 21.66 -24.38
EPS Growth (%) arrow
9.17 36.68 277.72 25.42 -21.99
Book Value Growth (%) arrow
15.86 11.36 22.95 18.43 11.27

Valuation Ratios

 Gujarat Themis Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
83.28 33.49 50.78 25.81 50.41
Price / Book Value arrow
4.62 6.61 12.50 4.61 6.75
Dividend Yield (%) arrow
0.18 0.20 0.17 0.38 0.56
EV/EBITDA arrow
60.64 18.34 32.92 18.27 34.99
Market Cap (₹ Cr) arrow
2,478.40 30,257.56 15,412.11 11,956.86 10,627.92

Solvency Ratios

 Gujarat Themis Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.45 0.05 0.09 0.00 0.00
Short term debt to equity ratio arrow
0.05 0.16 -- -- --
Current Ratio arrow
1.12 1.43 2.09 5.21 7.39
Quick Ratio arrow
0.93 0.82 1.37 3.85 5.46
Interest Coverage arrow
14.88 10.36 26.41 148.49 1,386.30

Operating Efficiency Ratios

 Gujarat Themis Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
35.06 26.46 22.82 41.42 41.52
Asset Turnover arrow
0.43 1.09 0.93 0.70 0.52
Receivable days arrow
101.42 88.68 77.32 144.58 169.86
Inventory Days arrow
22.53 84.11 80.83 96.67 97.92
Payable days arrow
469.41 176.65 125.94 135.45 159.68
Cash Conversion Cycle arrow
-345.46 -3.86 32.22 105.80 108.11
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...